AIM: GLP-1 receptor agonists (RAs) may cause nausea, vomiting or diarrhoea. The aim of this study was to assess the risk of adverse events (AEs) with GLP-1 RAs and their relation to dose, background medication and duration of action. RESEARCH DESIGN AND METHODS: The PubMed database was searched and 32 clinical trials with GLP-1 RAs (phase 3) were selected. We performed a systematic analysis and compared the proportion of patients reporting nausea, vomiting or diarrhoea, for different doses and glucose-lowering background medications, and relative to a reference compound within the subclasses of short- (exenatide b.i.d.) and long-acting (liraglutide) GLP-1 RAs, calculating the relative risks ± 95% confidence intervals. RESULTS: The risk of nausea was dose-dependent for long-acting (P = .0063) and across all GLP-1 RAs (P = .0017), and a similar trend was observed for vomiting (P = .23). Diarrhoea was dose-dependent (P = .031). Background treatment with metformin was associated with more nausea (P = .04) and vomiting (P = .0009). Compared to exenatide b.i.d., there was less nausea and diarrhoea with lixisenatide. Compared to liraglutide, there was a similar risk associated with dulaglutide, and less with exenatide q.w. and albiglutide. Long-acting GLP-1 RAs were associated with less nausea and vomiting, but with more diarrhoea than short-acting agents. CONCLUSIONS: GLP-1 RAs are associated with gastrointestinal AEs that are related to dose and background medications (especially metformin) and may vary in a compound-specific manner. Long-acting agents are associated with less nausea and vomiting but with more diarrhoea.
AIM: GLP-1 receptor agonists (RAs) may cause nausea, vomiting or diarrhoea. The aim of this study was to assess the risk of adverse events (AEs) with GLP-1 RAs and their relation to dose, background medication and duration of action. RESEARCH DESIGN AND METHODS: The PubMed database was searched and 32 clinical trials with GLP-1 RAs (phase 3) were selected. We performed a systematic analysis and compared the proportion of patients reporting nausea, vomiting or diarrhoea, for different doses and glucose-lowering background medications, and relative to a reference compound within the subclasses of short- (exenatide b.i.d.) and long-acting (liraglutide) GLP-1 RAs, calculating the relative risks ± 95% confidence intervals. RESULTS: The risk of nausea was dose-dependent for long-acting (P = .0063) and across all GLP-1 RAs (P = .0017), and a similar trend was observed for vomiting (P = .23). Diarrhoea was dose-dependent (P = .031). Background treatment with metformin was associated with more nausea (P = .04) and vomiting (P = .0009). Compared to exenatide b.i.d., there was less nausea and diarrhoea with lixisenatide. Compared to liraglutide, there was a similar risk associated with dulaglutide, and less with exenatide q.w. and albiglutide. Long-acting GLP-1 RAs were associated with less nausea and vomiting, but with more diarrhoea than short-acting agents. CONCLUSIONS:GLP-1 RAs are associated with gastrointestinal AEs that are related to dose and background medications (especially metformin) and may vary in a compound-specific manner. Long-acting agents are associated with less nausea and vomiting but with more diarrhoea.
Authors: Tito Borner; Jayme L Workinger; Ian C Tinsley; Samantha M Fortin; Lauren M Stein; Oleg G Chepurny; George G Holz; Aleksandra J Wierzba; Dorota Gryko; Ebba Nexø; Evan D Shaulson; Ankur Bamezai; Valentina A Rodriguez Da Silva; Bart C De Jonghe; Matthew R Hayes; Robert P Doyle Journal: Cell Rep Date: 2020-06-16 Impact factor: 9.423
Authors: T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp Journal: Mol Metab Date: 2019-09-30 Impact factor: 7.422
Authors: Cecilia Ratner; Zhenyan He; Kaare V Grunddal; Louise J Skov; Bolette Hartmann; Fa Zhang; Annette Feuchtinger; Anette Bjerregaard; Christina Christoffersen; Matthias H Tschöp; Brian Finan; Richard D DiMarchi; Gina M Leinninger; Kevin W Williams; Christoffer Clemmensen; Birgitte Holst Journal: Diabetes Date: 2019-04-01 Impact factor: 9.461
Authors: Shamina M Rangwala; Katharine D'Aquino; Yue-Mei Zhang; Lindsay Bader; Wilson Edwards; Songmao Zheng; Annette Eckardt; Ann Lacombe; Rebecca Pick; Veronica Moreno; Lijuan Kang; Wenying Jian; Eric Arnoult; Martin Case; Celia Jenkinson; Ellen Chi; Ronald V Swanson; Paul Kievit; Kevin Grove; Mark Macielag; Mark D Erion; Ranabir SinhaRoy; James N Leonard Journal: Cell Metab Date: 2019-02-14 Impact factor: 27.287
Authors: Riley Merkel; Amanda Moreno; Yafang Zhang; Rachel Herman; Jennifer Ben Nathan; Sana Zeb; Suditi Rahematpura; Kamryn Stecyk; Brandon T Milliken; Matthew R Hayes; Robert P Doyle; Heath D Schmidt Journal: Neurosci Biobehav Rev Date: 2021-10-29 Impact factor: 8.989
Authors: Christoffer Clemmensen; Brian Finan; Timo D Müller; Richard D DiMarchi; Matthias H Tschöp; Susanna M Hofmann Journal: Nat Rev Endocrinol Date: 2019-02 Impact factor: 43.330
Authors: Roseanne O Yeung; Mohammad Al Jundi; Sriram Gubbi; Maria E Bompu; Sandra Sirrs; Mark Tarnopolsky; Fady Hannah-Shmouni Journal: J Diabetes Complications Date: 2020-04-13 Impact factor: 2.852